Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Acute Myeloid Leukemia, LYT-200 and Fast Track
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
Mersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660
Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track
Yen on MSN
1d
20-year-old Ghanaian man battles leukemia, family seeks support for treatment
A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
14h
Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Hosted on MSN
1h
How Is Leukemia Diagnosed?
Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
Oncology Nurse Advisor
2d
No Change in Health-Related QoL Observed With Gilteritinib Maintenance Therapy in AML
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
The American Journal of Managed Care
3d
Functional Precision Medicine Tool Predicts Treatment Response in AML
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
1h
Aptose Biosciences, Inc.: Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing ...
3d
on MSN
Blood drive honors Cranston high school teacher battling cancer
A special blood drive was held Monday afternoon to honor a Cranston High School East teacher battling leukemia.
The American Journal of Managed Care
2d
Studies Examine Real-World Pediatric AML Treatment and Outcomes
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
Targeted Oncology
2d
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...
2d
on MSN
New family of protein-based antagonists shows promise against leukemia
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback